Trial Outcomes & Findings for Pharmacist Intervention to Improve Smoking Cessation (NCT NCT06943287)
NCT ID: NCT06943287
Last Updated: 2026-08-31
Results Overview
The number of phone calls the intervention participants complete with the research pharmacist.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
80 participants
Primary outcome timeframe
12 weeks
Results posted on
2026-08-31
Participant Flow
Participant milestones
| Measure |
Pharmacist Intervention Group
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
|---|---|---|
|
Overall Study
STARTED
|
42
|
38
|
|
Overall Study
COMPLETED
|
35
|
30
|
|
Overall Study
NOT COMPLETED
|
7
|
8
|
Reasons for withdrawal
| Measure |
Pharmacist Intervention Group
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
|
Overall Study
Lost to Follow-up
|
6
|
7
|
Baseline Characteristics
1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
Baseline characteristics by cohort
| Measure |
Pharmacist Intervention Group
n=42 Participants
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
n=38 Participants
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
Total
n=80 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
64.6 Years
STANDARD_DEVIATION 5.4 • n=42 Participants
|
63.3 Years
STANDARD_DEVIATION 6.1 • n=38 Participants
|
64.0 Years
STANDARD_DEVIATION 5.8 • n=80 Participants
|
|
Sex: Female, Male
Female
|
28 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
|
21 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
|
49 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
|
|
Sex: Female, Male
Male
|
13 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
|
10 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
|
23 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their sex is unknown; 7 participants in the Control Group did not complete the baseline survey, so their sex is unknown.
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
2 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
2 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
3 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
4 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Race (NIH/OMB)
White
|
34 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
28 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
62 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Race (NIH/OMB)
More than one race
|
2 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
2 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
0 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
2 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their race is unknown; 7 participants in the Control Group did not complete the baseline survey, so their race is unknown.
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
0 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
0 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
35 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
28 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
63 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
6 Participants
n=41 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
3 Participants
n=31 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
9 Participants
n=72 Participants • 1 participant in the Pharmacist Intervention Group did not complete the baseline survey, so their ethnicity is unknown; 7 participants in the Control Group did not complete the baseline survey, so their ethnicity is unknown.
|
|
Region of Enrollment
United States
|
42 Participants
n=42 Participants
|
38 Participants
n=38 Participants
|
80 Participants
n=80 Participants
|
PRIMARY outcome
Timeframe: 12 weeksPopulation: Participants in the Control Group did not complete phone calls with the pharmacist.
The number of phone calls the intervention participants complete with the research pharmacist.
Outcome measures
| Measure |
Pharmacist Intervention Group
n=287 Phone Calls
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
|---|---|---|
|
Number of Interactions With Pharmacist
|
183 Phone Calls
|
0 Phone Calls
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: Number of Nicotine Replacement Therapies used by the Control Group was not measured.
The number of participants who use nicotine replacement therapies during the study.
Outcome measures
| Measure |
Pharmacist Intervention Group
n=41 Participants
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
|---|---|---|
|
Number of Nicotine Replacement Therapies Used to Quit Smoking
|
12 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 12 weeksPopulation: Number of Non-Medication Tools used by the Control Group was not measured.
The number of participants who use non-medication tools to quit smoking.
Outcome measures
| Measure |
Pharmacist Intervention Group
n=35 Participants
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
|---|---|---|
|
Number of Non-Medication Tools Used to Quit Smoking
|
27 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 12 weeksThe number of participants who have successfully quit smoking at the end of the study.
Outcome measures
| Measure |
Pharmacist Intervention Group
n=35 Participants
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
|
Control Group
n=30 Participants
If the patient is randomized to the control group, they will only complete an exit survey 12-weeks later that asks if they are still smoking (and if they have quit, the date that they quit) and if they still use vapes, chew, and/or cigars/pipes.
|
|---|---|---|
|
Number of Successful Quit Attempts
|
8 Participants
|
3 Participants
|
Adverse Events
Pharmacist Intervention Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place